Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer-Reference-Cited by-同舟云学术

Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer

Published:2017-11 Issue: Volume:86 Page:197-206
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Suenaga Mitsukuni^ORCID,Schirripa Marta,Cao Shu,Zhang Wu,Yang Dongyun,Dadduzio Vincenzo,Salvatore Lisa,Borelli Beatrice,Pietrantonio Filippo,Ning Yan,Okazaki Satoshi,Berger Martin D.,Miyamoto Yuji,Gopez Roel,Barzi Afsaneh,Yamaguchi Toshiharu,Loupakis Fotios,Lenz Heinz-Josef

Funder

Takashi Tsuruo Memorial Fund

Swiss Cancer League

Werner and Hedy Berger-Janser Foundation of Cancer Research

Japan Society for the Promotion of Science

National Institutes of Health

Gloria Borges Wunderglo Project

Dhont Family Foundation

Dave Butler Research Fund

Call to Cure Research Fund

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors;Hong;Cancer,2006

2. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies;Temmink;Cancer Sci,2007

3. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells;Bijnsdorp;Int J Cancer,2010

4. Discovery and development of clofarabine: a nucleoside analogue for treating cancer;Bonate;Nat Rev Drug Discov,2006

5. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases;Jordheim;Nat Rev Drug Discov,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial;British Journal of Cancer;2024-09-07

2. Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy;Cancer Drug Resistance;2024-07-18

3. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status;Oncotarget;2024-07-02

4. Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias;BMC Cancer;2023-11-08

5. Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities;Pharmacology & Therapeutics;2022-12